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Available online 11 April 2019Background: High-density lipoproteins (HDL) are a complex mixture of lipids and proteins with
vasculoprotective properties. However, HDL components could suffer post-translational modiﬁcations (PTMs)
under pathological conditions, leading to dysfunctional HDL.We studiedwhetherHDL aremodiﬁed in abdominal
aortic aneurysm (AAA) and the effect on HDL functionality.
Methods: HDL were isolated by ultracentrifugation from AAA tissue (HDL-T) and from plasma of healthy volun-
teers and then incubated with AAA tissue-conditioned medium (HDL-AAA CM). PTMs from these particles were
characterized using Comet-PTM. The ability of HDL-AAA CM for promoting cholesterol efﬂux was determined
ex vivo and in vivo by using J774A.1 [3H]cholesterol-labeled mouse macrophages and after injecting [3H]choles-
terol-labeled mouse macrophages and HDL into the peritoneal cavity of wild-type C57BL/6 mice, respectively.
Trp50 and Trp108 oxidized forms of APOA1 inHDL incubatedwith conditioned-mediumof activated neutrophils
and in plasma of AAA patients and controls were measured by targeted parallel reaction monitoring.
Findings: Oxidation was the most prevalent PTM in apolipoproteins, particularly in APOA1. Trp50 and Trp108 in
APOA1 were the residues most clearly affected by oxidation in HDL-T and in HDL-AAA CM, when compared to
their controls. In addition, cholesterol efﬂux was decreased in macrophages incubated with HDL-AAA CM
in vitro and a decreased macrophage-to-serum reverse cholesterol transport was also observed in mice injected
with HDL-AAA CM. Finally, both oxidized Trp50 and Trp108 forms of APOA1 were increased in HDL incubated
with conditioned-medium of activated neutrophils and in plasma of AAA patients in relation to controls.
Interpretation:Oxidativemodiﬁcations of HDL present in AAA tissue and plasmawere closely associatedwith the
loss of vasculoprotective properties of HDL in AAA.
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© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Abdominal aortic aneurysm
HDL
Oxidative stress
Proteomics
Cholesterol efﬂux
Biomarkersar Research Lab., IIS-Fundación
, 28040 Madrid, Spain.
Proteomics Laboratory, Centro
II (CNIC), Melchor Fernández
vestigacions Biomèdiques (IIB),
, jvazquez@cnic.es (J. Vázquez),
. This is an open access article under1. Introduction
Abdominal aortic aneurysm (AAA) is a permanent focal dilation of
the abdominal aorta [1]. AAA is characterized by the presence of an
Intra Luminal Thrombus (ILT), mainly composed by red blood cells
(RBCs), neutrophils and platelets and an aortic wall with few vascular
smooth muscle cells (VSMC) in the remaining media, along with im-
mune cell inﬁltrates, ﬁbroblasts and neovessels in the adventitia [2].
Main mechanisms of AAA include proteolysis, oxidative stress andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Epidemiological studies have clearly demonstrated an inverse as-
sociation of high-density lipoproteins (HDL) cholesterol levels
with different (cardio)vascular diseases (CVD), including abdomi-
nal aortic aneurysm (AAA). However, different clinical trials
aimed at increasing HDL cholesterol levels failed to show benefi-
cial effects on CVD prevention. In this respect, it has been pro-
posed that HDL cholesterol levels are not causally related with
cardiovascular diseases (CVD) and that HDL functionality could
underlie the negative association of HDL cholesterol with CVD. In-
terestingly, increasing HDL functionality by different approaches
prevented AAA development in murine experimental models.
HDL are a complex mixture of lipids and proteins and the
vasculoprotective properties of HDL are associated to its compo-
nents. Previousworks including our own have showna differential
composition, and a loss of protective functions, of HDL isolated
from AAA patients as compared to HDL from controls. Moreover,
it has been demonstrated that HDL and its main component,
APOA1, could be oxidatively modified in atherosclerotic plaques,
leading to dysfunctional HDL. AAA is characterized by increased
oxidative responses and by increased tissular APOA1/HDL reten-
tion, but whether HDL are oxidatively modified in AAA has not
been explored before.
Added value of this study
By using novel proteomics approaches (COMET-PTM) recently de-
veloped in our lab, we have analyzed the PTMs of HDL recovered
from AAA tissues. Our results highlight a predominant role of ox-
idative modifications, mainly associated to APOA1, in HDLs. Spe-
cifically, we have shown for the first time a high susceptibility of
some residues of APOA1 (Trp50 and Trp108) in HDL recovered
from AAA tissue. Moreover, our results demonstrate that HDL
modification under AAA thrombus environment is associated to
dysfunctional HDL, characterized by decreased cholesterol efflux
capacity in vitro and in vivo. Finally, our results in plasma suggest
that oxidized Trp50 and Trp108 are new potential biomarkers of
AAA, potentially reflecting the increased oxidative stress involved
in this pathology.
Implications of all the available evidence
This translational study aimed to investigate potential PTMs of
HDL isolated from human tissue AAA samples, supporting an im-
portant role of oxidative stress in themechanisms underlying AAA
formation. Moreover, we have shown that HDL under AAA envi-
ronment loss their main function, namely cholesterol efflux capac-
ity. Finally, due to the circulating nature of HDL, we have shown
that some of the oxidative forms of APOA1 detected in tissue
are also increased in plasma of AAA patients suggesting that
they could be useful as surrogate systemic metrics of tissue-HDL
functionality.
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AAA pathophysiology could lead to novel diagnostic, prognostic and/
or therapeutic biomarkers.
The association of lipids with AAA has been controversial [4–6].
However, recent genetic studies suggest that lipids could play a role in
the etiology of AAA [7–10]. Similarly, the effect of statins on AAA
displayed contradictory results, although more recent studies supporta protective role of these drugs in preventing AAA growth and rupture
[11–13]. Regardless of the potential contribution of lipids on AAA pro-
gression, it is well accepted that low levels of high-density lipoprotein
(HDL) cholesterol are associated to both AAA presence and evolution
[14,15]. Moreover, raising HDL inhibits AAA formation and progression
in experimental models [16,17]. These data support the notion that in-
creasing HDL levels could have a beneﬁcial effect to prevent AAA devel-
opment. However, it is nowadays being accepted that the quality of
HDL is the relevant factor for its vasculoprotective activities [18]. Cardio-
vascular protective functions of HDL include reverse cholesterol trans-
port (RCT), as well as antioxidant, anti-inﬂammatory, antiapoptotic
and antithrombotic effects. Regarding AAA, we previously demon-
strated that HDL particle carries lower alpha-1 antitrypsin and higher
myeloperoxidase (MPO) proteins, leading to HDL with decreased
antiapoptotic and antioxidant properties [19,20]. Moreover, systemic
paraoxonase-1 activity, a surrogate marker of HDL (antioxidant) func-
tionality, is decreased in AAA patients [21]. More recently, we have
shown that AAA patients display impairedHDL cholesterol efﬂux capac-
ity, the ﬁrst step of RCT [22]. All these data suggest that HDL could be
dysfunctional due to impaired concentration or function of speciﬁc mo-
lecular components of the particle in AAA. In this respect, APOA1, the
main protein constituent of HDL, could be oxidatively modiﬁed in
human atherothrombosis, leading to dysfunctional HDL [23,24]. As we
previously observed that human AAA tissue (ILT and wall) was charac-
terized by increased oxidation capacity [20] and by high APOA1 immu-
nostaining [15]we thus hypothesized that human AAA tissue could be a
privileged site for searching APOA1/HDL oxidative modiﬁcations.
In the present paper, we used state of the art proteomics approaches
very recently developed [25] to characterize the post-translational
modiﬁcations (PTMs) on HDL and the changes suffered by the particles
in the context of AAA from a completely hypothesis-free perspective.
We analyzed PTM alterations in HDL isolated from tissue of AAA pa-
tients. We then studied whether these alterations could be reproduced
in plasma-isolated HDL incubated with AAA tissue- conditioned me-
dium (HDL-AAA CM) and whether they affected HDL functionality.
The ability of HDL-AAA CM for promoting macrophage cholesterol ef-
ﬂux was determined ex vivo and in vivo by using mouse macrophages
and after injecting them along with HDL into the peritoneal cavity of
mice. Finally, we explored the potential role of these modiﬁcations as
circulating biomarkers of AAA.
2. Material and methods
2.1. Data statement
Datasets have been deposited in PeptideAtlas (dataset identiﬁer
PASS01347).
2.2. Tissue and tissue-conditioned medium
Tissue samples (ILT and wall) were collected during surgical repair
from AAA patients and kept at −80° until further processed. Ethical
committee advice and patient informed consent were obtained
(RESAA and AMETHYST studies, CPP Paris-Cochin n° 2095, 1930 and
1931, Inserm Institutional Review Board, IRB0000388). Healthy abdom-
inal aortaswere sampled from deceased organ donors with the authori-
zation of the French Biomedicine Agency (PFS 09–007). Tissue-
conditioned medium was obtained as described [26].
2.3. HDL isolation
Tissue [100mg of AAA intraluminal thrombus (HDL-ILT), AAA path-
ological wall (HDL-PW) and healthy aortic wall (HDL-HW)] was ho-
mogenized and care was taken throughout homogenization to
maintain a low temperature by keeping the homogenization vessel sub-
merged within liquid N2. After that, lysates were resuspended in buffer
45D. Martínez-López et al. / EBioMedicine 43 (2019) 43–53(BR20x, FIP, CIP, PMSF, 1 mM EDTA, Tris-HCL pH 8.5). Samples were
vortexed every 15 min for a total of 4 times and kept on ice.
The supernatantwas obtained after centrifugation at 12,000 rpm for 15-
min. Then, lipoproteins were isolated from these tissue supernatants
or from EDTA plasma samples of healthy volunteers by ultracentrifuga-
tion as described [27]. Plasma density was adjusted to ρ= 1.063 g/mL
with KBr and the sample was overlaid with KBr saline solution (ρ =
1.063 g/mL). Samples were ultracentrifuged at 53000 rpm for 18 h
at 4 °C in a TLA-100 rotor (Beckman). After centrifugation, the upper,
apolipoprotein-B-containing fraction was recovered and stored.
The bottom fraction, containing whole HDL, was adjusted to 1.25 g/mL
with KBr and overlaid with KBr saline solution (ρ = 1.22 g/mL).
The HDL-containing fraction was then ultracentrifuged at 63000 rpm
for 24 h at 4 °C. After this step, HDL, in the top layer, were recovered
as a single band and were extensively rinsed with saline and concen-
trated using a centrifugal concentrating device (cutoff 10 kDa). All
HDL samples were desalted by centrifugation and 3 washes with saline.
In some cases, HDL isolated from plasma were incubated with AAA
ILT-conditioned medium (HDL-ILT CM) or with PBS (HDL-control) for
4 h (1:1 proportion), and then reisolated by ultracentrifugation. The
protein composition of these particles is shown in Supp. Figs. 1 and 2.
Finally, we isolated neutrophils from blood of healthy volunteers and
stimulated 5x106 cells with phorbol 12-myristate 13-acetate (PMA,
3.2uM) (Sigma-Aldrich) for 30 min at 37 °C as described [28]. Then
cells were centrifuged at 12000 rpm5min at 4°C and the corresponding
supernatant of activated neutrophils was obtained and incubated with
HDL for 4 h at 37 °C and then reisolated by ultracentrifugation.
2.4. Plasmas
Plasmas were obtained from 27 patients with an asymptomatic
infrarenal AAA (aortic size N3 cm). AAA patients were recruited from
January 2010 to December 2016 at IIS–Fundacion Jimenez Diaz
(Table 1). The presence of cardiovascular risk factors, such as diabetes
mellitus, arterial hypertension, dyslipidemia, and smoking habits,
were assessed. Patients were considered as diabetics if they were
under treatment (supervised diet, hypoglycemic oral medication, and
insulin) or a basal glycemia N120 mg/dL and/or glycosylated hemoglo-
bin N6.5%. We deﬁned hypertension as SBP N140 mmHg and/or DBP
N90 mmHg measured during the examination (after the participant
had been sitting for at least 30min) or if the participantwas already tak-
ing hypotensive medication. Dyslipidemia was diagnosed as the pres-
ence of at least 1 of the following characteristics: total cholesterol
N5.2 mmol/L; LDL-cholesterol N3.4 mmol/L, or triglycerides
N2.3 mmol/L; or the participant was already taking statins or ﬁbrates
medication. Smoking was deﬁned as current smokers or nonsmokers
(including ex-smokers, those who stopped smoking at least 6 months
before the inclusion in the study), with a smoker deﬁned by the history
of smoking (≥10 cigarettes per day N1 year). Controls with no AAA (n=
28)were recruited from a screening program for AAA between 65-year-
old men. The absence of AAA was conﬁrmed with a physical examina-
tion and an ultrasound scan (aortic size b3 cm).
The ethical committee on human research at IIS, Fundacion Jimenez
Dıaz, Autonoma University (Madrid, Spain) approved the study, whichTable 1
Clinical characteristics of controls and AAA patients.
Control (n = 28) AAA patients (n= 27) p-Value
Age (years) 64.9 ± 0.1 67.7 ± 0.9 b0.001
Sex (male/female) 28/0 27/0
Hypertensive (%) 53 ± 9 63 ± 9 0.221
Smokers (%) 64 ± 9 40 ± 9 0.463
Diabetes (%) 32 ± 8 25 ± 8 0.322
Dyslipidemic (%) 50 ± 9 44 ± 9 0.564was performed in accordwith the principles outlined in the Declaration
of Helsinki, and all participants gave written informed consent.
2.5. Proteomics
2.5.1. Sample preparation
Samples (200 μg of total proteins of HDL)were digested overnight at
37 °C in FASP ﬁlters with trypsin (Promega, Madison, WI, USA) at an
40:1 protein:trypsin (w/w) ratio in 50 mM ammonium bicarbonate,
pH 8.8. The resulting peptides were desalted on C18 Oasis cartridges
(Waters Corporation, Milford, MA, USA) using 50% acetonitrile (ACN)
(v/v) in 0.1% triﬂuoroacetic acid (v/v) as eluent, and vacuum dried.
The peptides were then subjected to isobaric TMT labelling following
manufacturer's instructions. HDL samples isolated from tissue (healthy
wall, AAA pathological wall and ILT) were analyzed in three biological
replicates. An internal control was constructed by pooling the three
samples from the healthywall andwas used as reference to express rel-
ative quantiﬁcation values. HDL isolated from plasma of healthy volun-
teers were incubated with ILT-conditioned media or PBS. An internal
control was constructed by pooling HDL incubated with PBS and was
used as reference to express relative quantiﬁcation values.
2.5.2. LC-MS analysis
Peptide samples were analyzed using an Easy nano-ﬂow HPLC sys-
tem (Thermo Fisher Scientiﬁc, Bremen, Germany) coupled via a
nanoelectrospray ion source (Thermo Fisher Scientiﬁc) to a Q Exactive
HF mass spectrometer (Thermo Fisher Scientiﬁc). C18-based reverse
phase separation was used with a 2-cm trap column and a 50-cm ana-
lytical column (EASY column, Thermo Fisher Scientiﬁc).
For the study of PTMs, peptides were loaded in buffer A (0.1% formic
acid (v/v)) and eluted with a 180-min linear gradient of buffer B (80%
acetonitrile, 0.1% formic acid (v/v)) at 200 nL/min. Mass spectra were
acquired in a data-dependent manner, with an automatic switch be-
tweenMS andMS/MS using a top 15method.MS spectrawere acquired
in the Orbitrap analyzer with amass range of 400–1500m/z and 60,000
resolution. HCD fragmentation was performed at 27 normalized colli-
sion energy and MS/MS spectra were analyzed at 60,000 resolution in
the Orbitrap.
For the parallel reaction monitoring assays, peptides were loaded in
buffer A and eluted with a 90 min linear gradient of buffer B at
200 nL/min. MS spectra were acquired in the Orbitrap analyzer with a
mass range of 400–1500 m/z and 15,000 resolution followed by data-
independentMS/MS spectra of selected precursor ions. HCD fragmenta-
tion was performed at 27 of normalized collision energy and MS/MS
spectrawere analyzed at 60,000 resolution in theOrbitrap. Data analysis
was performed with Xcalibur 2.2 (Thermo Scientiﬁc).
2.5.3. Database search
For protein identiﬁcation, searches were performed with Comet re-
lease 2016.01 using 5 ppm precursor ion tolerance, Met oxidation as
a dynamic modiﬁcation, trypsin digestion with 1 missed cleavage
(unless otherwise speciﬁed) and ﬁxed Cys carbamidomethylation
(57.021464 Da) [29,30]. TMT labeling at N-terminal end and Lys was
also considered as a ﬁxed modiﬁcation (229.162932 Da). Fragment ion
tolerance was 0.02 bin, 0 mass offset. Precursor tolerance type and iso-
tope error were set to 1. Precursor charge range was 2–4, maximum
precursor charge 5 and maximum fragment charge 3. Only y- and b-
ions were used for scoring. Peptide identiﬁcation from MS/MS data
was performed using the probability ratio method [31]. False discovery
rates (FDR) of peptide identiﬁcations were calculated using the reﬁned
method [32]; 1% FDR was used as the default criterion for peptide
identiﬁcation.
2.5.4. Comet-PTM
For PTM analysis, open searches using a precursor ion tolerance of
500 Da were performed using Comet-PTM, as described [25]. Comet-
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tween theoretical and experimental precursor mass (DMass), and adds
up thismass iteratively to each one of the amino acidmasses in the pep-
tide sequence, calculating a Xcorr score in each one of the possiblemod-
iﬁed forms of the peptide. The selected candidate is the modiﬁed
peptide form that produces the highest Xcorr. Comet-PTM produces
the same score than Comet with a preselected modiﬁcation, with the
difference that Comet-PTM identiﬁes all possible modiﬁcations within
+− 500 Da of precursor ion [25]. The accuracy of Comet-PTM to assign
themodiﬁcation to the correct site has been estimated to be between 80
and 85% using both high-throughput data and synthetic peptides [25].
2.5.5. SHIFTS
SHIFTS (Systematic Hypothesis-free Identiﬁcation of modiﬁcations
with controlled FDR based on ultra-Tolerant database Search) was
used to identify peaks in the DMass distribution, assign PSMs to peaks
and calculate the FDR for peptide identiﬁcation. Further details about
SHIFTS are described in.25
2.5.6. Annotation of modiﬁcations
An in-house developed script was used for the semisupervised an-
notation of peptide modiﬁcations as described [25]. Brieﬂy, the script
matches DMass values against the Unimod database, considering the
amino acid modiﬁcation positions revealed by Comet-PTM as well as
the preceding and following residues. For simplicity, artifactual modiﬁ-
cations introduced during sample preparation and modiﬁcations that
could not be annotated in Unimod were not considered in further anal-
ysis. Met mono-oxidation (+16 Da) is not considered as a PTM.
2.5.7. Peptide quantiﬁcation and statistical analysis
The quantitative information from TMT reporter intensities was in-
tegrated from the spectrum level to the peptide level and then to the
protein level on the basis of theWSPP model using the Generic Integra-
tion Algorithm (GIA), as described [25,33,34]. The algorithmwas modi-
ﬁed to incorporate the quantitative values of modiﬁed peptides as part
of the automated workﬂow [25]. Hence, quantitative peptide values
are referred to the weighted averages of the non-modiﬁed peptides
from the same protein and therefore are not affected by protein abun-
dance changes [25]. This statistical model describes accurately the
error distribution of abundance changes of both non-modiﬁed and
modiﬁed peptides in null hypothesis experiments [25]. Signiﬁcant
abundance changes of modiﬁed peptides across the different samples
were detected by Student's t-test.
2.6. Immunohistochemistry
Samples of ILT and wall obtained from AAA and healthy arterial wall
were embedded in parafﬁn, and 4 μmcross-sectionswere cut. Immuno-
histochemistry was performedwith antibodies against APOA1 (ab7613,
abcam) and the lipid peroxidationmarkerMDA (ab6463, abcam), as de-
scribed [35].
2.7. Lipoprotein oxidation
Wemeasured basal HDL conjugated dienes at 234 nmby using a 96-
microwell plate for UV detection. HDL was also oxidized with 2.5 μM
CuSO4 and the oxidation kinetics was followed by continuousFig. 1. PTMs in lipid metabolism proteins in HDL recovered from AAA tissue. (A) Peptide-spect
among proteins pertaining to lipid metabolism. (B) Adscription of the PSMs corresponding to p
posttranslationally modiﬁed and unmodiﬁed peptides from APOA1. (D) PSM distribution of o
(yellow, increased in thrombus; violet, decreased). (E) Abundance changes of oxidativel
standardized log2 ratio Zpq [n=3, p b .05 labeled in green, t-test]; other differentially abundant
in human AAA tissue. No staining for APOA1 ormalondialdehyde is observed in negative contro
phorylation; Methyl: Methylation; AGE: Advanced glycation end product; Kyn: Kynurenine; ox
oxidation in Met (marked in light blue in A and C) are included in the group of unmodiﬁed pemonitoring of conjugated diene formation at 37 °C for 1 h. The lag
phase was calculated from the intersection point between the maximal
slope of the curve and initial absorbance.
2.8. Cholesterol efﬂux analyses
Cholesterol efﬂux capacity to HDL-control or HDL-ILT CM (50 μg/mL
APOA1) was determined by using J774A.1 [3H]-cholesterol-labeled
macrophages after loaded with acetylated (ac)-LDL as previously re-
ported [36]. Ten to 12 weeks-old female wild-type C57BL/6 mice re-
ceived intraperitoneal injections of HDL-control or HDL-ILT CM (100
μg APOA1) together with [3H]cholesterol-labeled J774 macrophages.
Mice were randomized into two groups and the HDL injections were
performed blinded by the technician. Cell viability of the macrophage
preparations ranged from 85 to 90% and each mouse received an i.p.
dose of [3H]cholesterol-labeled mouse macrophages (0.92 × 105 cells/
mouse, 0.99 × 105 cpm/mouse). Serum [3H]cholesterolwas determined
after 3 h of the macrophage injection as described [36]. All mice were
kept in a temperature-controlled environment (20 °C) with a 12-h
light/dark cycle and maintained on a regular chow diet (Safe, Scientiﬁc
Animal Food & Engineering; A04C, 3% fat, 2900 kcal/kg). Food andwater
were provided ad libitum. All animal procedures were conducted in ac-
cordancewith published regulations and reviewed and approved by the
Institutional Animal Care Committee of the Institut de Recerca of the
Hospital de la Santa Creu i Sant Pau (ref. 7281).
2.9. Statistics
Results are shown asmean± standard deviation. In vitro and in vivo
data was analyzed by t-test or Mann-Whitney test, respectively. Multi-
variate logistic regresion analysis was completed to identify the impact
of different variables on the prediction of AAA. Statistical differences in
c-statistics were compared using the method by DeLong et al. [37];
95% CIs were calculated for each comparison. P value b.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. Characterization of PTMs of HDL-like particles recovered from AAA tis-
sue highlights APOA1 oxidation
To analyze whether HDL are modiﬁed in the context of AAA, we de-
cided to recover HDL-like particles from homogeneized AAA tissue [ILT
(HDL-ILT) and pathological wall (HDL-PW)] and from healthy aortic
wall (HDL-HW) by ultracentrifugation.
High-throughput analysis of PTMs using Comet-PTM revealed that
one third of peptides from lipid metabolism proteins had modiﬁcations
that could be assigned to known PTMs,while two-thirds of the peptides
were non-modiﬁed (Fig. 1A). Oxidation accounted for the majority of
modiﬁcations in HDL-like particles (Fig. 1A and Supp. Table 1). Thema-
jority of PTMs were found in APOA1 (Fig. 1B). Of note, the proportion of
modiﬁed peptides in APOA1 was higher than in the rest of proteins
(Fig. 1C). Oxidative modiﬁcations in APOA1 affected mainly Trp resi-
dues, while Tyr, Pro, His, Asp, Met and Lys were also affected, although
to a lesser extent (Fig. 1D). Quantitative analysis taking as reference
the peptides from the same protein that were not modiﬁed revealed
that the pattern of PTM changes suffered by APOA1 peptides wasrum matches (PSM) distribution of posttranslationally modiﬁed and unmodiﬁed peptides
osttranslationally modiﬁed peptides to lipid metabolism proteins. (C) PSM distribution of
xidative PTMs in APOA1 according to the modiﬁed residue and their abundance change
y modiﬁed ApoA1 peptides as compared to healthy tissue expressed in terms of the
modiﬁcations are shown in Supp. Fig. 4. (F) Colocalization of ApoA1 andmalondialdehyde
ls (scale bar= 100uM). DeA: Deamidation; MethylMal: Methylmalonylation;Phos: Phos-
, 2ox and 3ox: addition of one, two or three oxygens, respectively. Peptides with a single
ptides.
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Fig. 3. Macrophage cholesterol efﬂux to HDL-ILT CM and HDL-control in vitro and
macrophage -to-serum reverse cholesterol transport (RCT) in vivo. (A) Ability of HDL-
ILT CM and HDL-control (HDL-C) for promoting cholesterol efﬂux from J774A.1 [3H]
cholesterol-labeled mouse macrophages. After 4 h of incubation, efﬂux of cholesterol
was determined and expressed as [3H]cholesterol medium /([3H]cholesterol cells +
[3H]cholesterol medium) x 100. Values are means ± SEM of four independent HDL per
group. (B) Macrophage-to-serum RCT after injecting intraperitoneally with [3H]
cholesterol-labeled mouse macrophages and HDL-ILT CM or HDL-control. Macrophage-
derived [3H]cholesterol radioactivity was measured at 3 h post-macrophage injection in
serum. Values are means ± SEM (N = 8 individual mice for HDL-control, N = 7 for
HDL-ILT CM). [*p ≤ .05 vs HDL-control, t-test].
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HDL-HW (Fig. 1E). A generalized increase in the abundance of peptides
bearing oxidized Trp forms in HDL-ILT andHDL-PW in comparisonwith
HDL-HW was observed (Fig. 1D). The peptides contained mono-, di-
and tri-oxidations and also Trp in the form of kynurenine (Fig. 1E). Pep-
tide forms containing the four Trp residues of APOA1 were detected by
mass spectrometry; from these, oxidation was found in three of them,
corresponding to Trp50, Trp72 and Trp108. This trendwas not detected
in peptides bearing oxidized forms in other aminoacids (Fig. 1E). Inter-
estingly, we found by immunohistochemistry that APOA1 in ILT and
wall of AAA colocalizes with malonaldehyde (MDA), a marker of lipid
peroxidation, which was not present in healthy aortic wall (Fig. 1F).
3.2. Incubation of plasmatic HDLwith AAA tissue-conditionedmedium pro-
duces APOA1 oxidation and impacts HDL functionality
Our previous results indicated that HDL-like particles retained in
AAA tissue are affected by speciﬁc oxidative modiﬁcations. We hypoth-
esized that oxidizing agents present in the AAA tissue caused this oxida-
tive damage on HDL and could affect HDL functionality.
In an attempt to reproduce themodiﬁcations taking place in the AAA
tissue environment, we performed an ex vivo approach preparing HDL
isolated from plasma of healthy volunteers and incubating them with
tissue-conditionedmedium (CM) during 4 h; then, HDLwere reisolated
by ultracentrifugation and subjected to proteomics analysis following
the same approach as above. However, as the limited amount of healthy
wall (and then, healthy-CM) to be used in the functional in vivo studies
made this task unfeasible, we decided to use HDL incubated with PBS
(HDL-control). We ﬁrstly conﬁrmed that healthy wall-CM did not pro-
duce oxidative HDL modiﬁcations when compared to HDL-control
(Supp. Fig. 3A). Analysis of HDL incubated with ILT-conditioned me-
dium (HDL-ILT CM) showed that the basal proportions of PTMs were
similar to those of HDL-like particles from ILT, being oxidativemodiﬁca-
tions themost abundant andAPOA1 the proteinmostly affected by PTM
(Fig. 2 A-C and Supp. Table 1). Quantitative analysis conﬁrmed the gen-
eralized increase of peptides bearing oxidized Trp forms in the HDL-ILT
CM samples in comparison to those from HDL-control (Fig. 2D). In this
case, oxidation affected to Trp50 and Trp108 (Fig. 2E). Finally, to analyze
if incubation of HDL with ILT CM also produces oxidation at the lipid
level, we evaluated the basal HDL conjugated dienes. HDL-ILT CM had
signiﬁcantly increased basal levels of conjugated dienes when com-
pared with those of HDL-control (Fig. 2F). Moreover, we also evaluated
the potential of HDL-ILT CM to be further oxidized in an experimental
system, in which isolated HDL were exposed to the prooxidant Cu2+.
Under these conditions, HDL-ILT CM exhibited a signiﬁcantly shorter
lag phase when compared with HDL-control, indicating that extensive
oxidation was promoted earlier in the HDL-ILT CM (Fig. 2G).
Then, we used theHDL-ILT CMparticles to interrogate the functional
consequences that oxidative modiﬁcations may produce on HDL. We
ﬁrstly conﬁrmed that incubation of HDL with healthy wall-CM did not
affect the ability of macrophages to act as acceptors of cholesterol
ex vivo when compared with HDL-control (Supp. Fig. 3B). In contrast,
when HDL-ILT CM particles were added to macrophages, we found
that their ability to promote cholesterol efﬂux was blunted compared
with HDL-control (Fig. 3A). Moreover, to study the in vivo effect of
HDL-ILT CM, [3H]cholesterol-labeled J774A.1 macrophages were
injected together with HDL into the peritoneal cavity of mice. Three
hours after injection of the macrophages, [3H]cholesterol in plasmaFig. 2. PTMs in lipid metabolism proteins from HDL incubated with AAA ILT-conditioned medi
labeled in green, t-test]. Other differentially abundantmodiﬁcations are shown in Supp. Fig. 5. (F
(HDL-C). (G) Lag phases of HDL-ILT CM and HDL-C in the presence of CuSO4. A shorter lag phas
Values are means± SEM of four independent HDL per group. *p ≤ .05 vsHDL-C [t-test]. For sim
the group of unmodiﬁed peptides. DeA: Deamidation, MethylMal: Methylmalonylation, Phos:was reduced in the HDL-ILT CM injected group as compared to HDL-
control (Fig. 3B).
3.3. Increased oxidized Trp50 and Trp108 of APOA1 in HDL incubated with
PMN-conditioned medium and in plasma of patients with AAA
Given the increased abundance of oxidized Trp in APOA1 observed
in HDL from AAA tissue or in HDL incubated with AAA-tissue condi-
tioned media, we tested potential cellular sources of ROS involved in
these oxidative processes. As it has been previously shown that MPO
is involved in APOA1 oxidation [23,24] and we previously showed in-
creasedMPO in HDL and PMNof AAA patients [19,28], we hypothesized
that oxidants (including MPO) released by activated PMNs could medi-
ate the oxidation of APOA1 in AAA. Then, we incubated HDL isolated
from plasma of healthy volunteers with the conditioned medium ob-
tained after activation of neutrophils with PMA; after that, HDL were
reisolated by ultracentrifugation.
To test speciﬁc APOA1 oxidation, we setup a targeted mass spec-
trometry assay (Fig. 4A and B) and used it to quantify non-modiﬁed
and oxidized Trp (Trp8, 50, 72 and 108)-containing peptides in HDL in-
cubated with conditioned medium of PMA-activated PMNs. The oxi-
dized form of Trp8 was not detected in this preparation. We observed
an increase of oxidation forms of Trp 50 and Trp 108 in HDL-
incubated with PMN-conditioned media (Fig. 4C). Moreover, oxidized
Trp72 was also increased (not shown), as previously observed in ath-
erosclerotic plaques [38] and here, in AAA tissue.
Finally, we hypothesized that oxidized Trp in APOA1 found in tissue
could also be present in plasma, where they could be used as circulating
surrogate markers of HDL dysfunction. To explore this possibility, we
used the same targeted mass spectrometry assay described above. The
oxidized forms of Trp8 and Trp72 could not be directly detected in
plasma; however, we could accurately monitor the oxidized Trp50
and Trp108peptide forms in control subjects andAAApatients. The pro-
portions of the dioxidized forms of both Trp50 and Trp108 wereum. (A, B, C, D and E) These graphs have the same meaning than in Fig. 1 [n= 4, p b .05,
) Basal levels of conjugated dienes inHDL-ILT CMcompared to those found inHDL-control
e indicates a higher susceptibility to be extensively oxidized under prooxidant conditions.
plicity, in (A) and (B) methionine-oxidized peptides (marked in light blue) are included in
Phosphorylation, Methyl: Methylation.
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Table 2
Multivariate statistical analysis of Trp50 and Trp108.
A) Plasma levels of dioxidized Trp50 and Trp108 in ApoA1 are independent
predictors of AAA
p-Value OR (95% CI) (1)
W50diox 0.008 2.22 (1.23–4.01)
W108diox 0.013 2.52 (1.21–5.25)
(1) OR for variables expressed in units of standard deviation. Logistic regression
was adjusted by age; no other risk factors were found to associate with AAA
B) Plasma levels of dioxidized Trp50 and Trp108 in ApoA1 improve prediction of
AAA over risk factors
AUC (95% CI)1 p-Value2 p-Value3
Age 0.65 (0.48–0.82) 0.050
W50diox 0.70 (0.56–0.84) 0.010
W108diox 0.79 (0.67–0.91) 0.020
Age, W50diox and W108diox 0.84 (0.73–0.95) b0.001 0.01
1 Area under the curve obtained by ROC analysis.
2 Statistical signiﬁcance vs reference value (AUC = 0.5).
3 Statistical signiﬁcance vs Age, DeLong's test.
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trols (Fig. 4C).
Multivariate logistic regression analysis also revealed that the pro-
portions of each one of the two dioxidized Trp forms were signiﬁcantly
associated to the presence of AAA after adjustment by age (Table 2A).
ROC analysis revealed that the proportions of the two dioxidized Trp
forms of APOA1 were good predictors of the disease (Table 2B). More-
over, a panel with the two dioxidized Trp forms signiﬁcantly increased
the power to predict AAA over age alone (Table 2B).
4. Discussion
In this work we have used state of the art proteomics approaches to
characterize the whole landscape of PTM in HDL and the speciﬁc alter-
ations under AAA tissue environment. We have used as models HDL-
like particles recovered from AAA tissue and HDL isolated from plasma
incubated with AAA tissue-conditioned media. To our knowledge, this
is the ﬁrst time that such a comprehensive, quantitative and
hypothesis-free analysis of PTM has been performed in HDL particles.
It is interesting to note that the majority of modiﬁcations found in
HDL are of oxidative nature; althoughHDL are known to suffer oxidative
modiﬁcations, theproportion of thesemodiﬁcationswith respect to that
of unmodiﬁed peptides and other potential modiﬁcations has never
been studied before. Our analysis revealed that the major hallmark of
AAA is the oxidative modiﬁcations on Trp residues in APOA1. We
were able to detect all Trp-containing peptides in APOA1, and those af-
fected by oxidation were found in different oxidation states, including
not onlymono- and di-oxidation, but also in kynurenine form, reﬂecting
gradual stages of oxidative damage. Other residues, like Tyr and Pro,
were also affected but to a lesser extent. Pro residues were presumably
hydroxylated. A remarkable ﬁnding of this study is that the abundance
of oxidative modiﬁcations in Trp was consistently increased in HDL-
like particles obtained from AAA tissue, a trend that was not detected
in other residues. This apparently selective effect of AAA-derived oxi-
dants on Trp residues was conﬁrmed when HDL particles isolated
from plasma of healthy individuals were incubated with conditioned
media obtained from ILT. All these results suggested that Trp residues
in APOA1 are the most sensitive to oxidants present in the human
AAA environment. These oxidantswere alsomanifested by the presence
of lipid oxidation products whose tissular distribution closely
colocalized with that of APOA1, suggesting the presence of oxidized
lipids and proteins in HDL particles retained in the AAA tissue.
Previous papers have shown that the oxidative modiﬁcation of dif-
ferent residues of APOA1 are present in atherosclerotic plaques and
are associated to HDL dysfunctionality [23,24]. In this work, by combin-
ing immunohistochemical and biochemical approaches in addition to
proteomics, we demonstrate for the ﬁrst time that APOA1/HDL is oxi-
dized within the AAA tissue environment. ILT in human AAA is charac-
terized by the presence of neutrophils and RBC, which are potent
sources of oxidative stress through the release of MPO and its
potentialization by redox-active Fe++ from free hemoglobin.We previ-
ously demonstrated that the levels ofMPO are higher in human AAA tis-
sue and tissue-conditioned medium [16]. MPO mainly released by
activated neutrophils, catalyzes the reaction between hydrogen perox-
ide and chloride ions to produce hypoclorous acid as the primary oxi-
dant. Interestingly, MPO is associated to HDL and we showed that HDL
from patients with AAA carries higher MPO levels as compared to HDL
from controls [19]. Speciﬁcally, we have nowdemonstrated that HDL in-
cubated with conditioned medium of activated neutrophils displayFig. 4. Targetedquantitative assay of Trp oxidation inHDL incubatedwith activatedneutrophils
plasma. The intensities of the y7+and y12+ fragmentswere used to quantify the different oxid
chromatograms corresponding to these fragments for representative AAA and control plasma s
with the supernatant (SN) of PMA-activated neutrophils as compared to HDL incubatedwith PB
Trp50 and Trp108 forms are signiﬁcantly increased inAAApatients (N=27) in relation to contr
forms is expressed as percentage in relation to the non-modiﬁed peptide.oxidative modiﬁcations similar to those observed in HDL-like particles
fromAAA tissue andHDL-ILT CM. Among those oxidativemodiﬁcations,
it has been previously observed that MPO is able to oxidize Trp72 [38],
which was conﬁrmed in our in vitro study. These data suggest that
neutrophil-derived oxidantsmay play a relevant role in APOA1/HDL ox-
idation in AAA tissue. We cannot, however, discard the contribution of
other sources of ROS such as red blood cell-derived ferrous iron (highly
abundant in AAA) [39] or other enzymatic sources. In these regard, neu-
trophil extracellular trap-derived enzymes such as nicotinamide ade-
nine dinucleotide phosphate (NADPH) oxidases have been shown to
oxidize HDL in autoinmune diseases [40].
The best-knownHDL's protective function is their ability to promote
cholesterol efﬂux from cells, including that frommacrophages in the ar-
terial wall. In the present study, we show that HDL-ILT CM particles are
characterized by decreased cholesterol efﬂux capacity (CEC). Since Trp
residues are key factors regulating theMPO-mediated loss of the choles-
terol acceptor activity of APOA1 [41], the oxidative modiﬁcations in Trp
residues described in this study could partially explain the decreased
CEC observed under our experimental conditions, although we cannot
discard the contribution of othermodiﬁcations. To further assess this ef-
fect in vivo, we used the peritoneal cavity as a surrogate to evaluate the
potential impact of HDL-ILT CM on macrophage-to-serum RCT in vivo.
Because of the highly turnover of HDL particles in the peritoneal ﬂuid
and the highly dynamic nature of the cholesterol efﬂux assay, we short-
ened our macrophage-speciﬁc RCT assay for directly assessing the local
effects of HDL-ILT CM, showing a decreased macrophage-to-serum
transport inmice injectedwith HDL-ILT CM. The importance of effective
cholesterol efﬂux in AAA is due to the fact that cholesterol crystals are
present in AAA wall, where they can contribute not only to immune re-
sponses but also to SMC death, two main mechanisms underlying AAA
progression.Whether therapies aimed at increasing HDL cholesterol ef-
ﬂux could prevent AAA progression deserves further studies. Interest-
ingly, we previously demonstrated that increasing HDL function by
using 4DF peptide (which is resistant to APOA1 oxidation) or by over-
expressing themajor HDL-antioxidant protein (PON-1), was able to de-
crease experimental AAA formation [15,21].
There is a great interest to ﬁnd biomarkers of HDL quality and func-
tion that can improve risk prediction and target drug treatments. Effortsandplasma fromAAApatients. (A) Quantitative PRManalysis of Trp-containing peptides in
ation states of Trp108 (left panels) and Trp50 (right panels), respectively. (B) Extracted ion
amples. (C) The abundance of oxidized Trp50 and Trp108 was increased in HDL incubated
S [4 h, n=3–6, ** p b .01 and * p b .05, t-test]. (D)The concentrations of the two dioxidized
ols (N=28) [* p b .05; *** p b .01,Mann-whitney test]. The abundance of the dioxidized Trp
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the potential functions of HDL are recognized as a major challenge in
the cardiovascularﬁeld. Growing evidence indicates an inverse relation-
ship between HDL CEC and the incidence of CVD [42]. We have recently
shown an impairment of macrophage CEC in ApoB depleted plasma
("plasma HDL") from AAA patients [22]. In addition to the analysis of
CEC in plasma HDL, other authors have measured oxidized forms of cir-
culating APOA1 in CVD [38,43]. In general, the authors focused on oxi-
dized forms of APOA1 which negatively regulated HDL functions and
that were detected in atherosclerotic plaques. In the largest study per-
formed to date, oxidized APOA1 (Trp72) was assessed in plasma using
speciﬁc antibodies [38]. In this work, we observed that oxidized forms
of Trp in APOA1 were increased within AAA tissue environment, and
also in HDL incubated with activated neutrophils, and tested whether
these forms could serve tomonitor a pathophysiologically relevant pro-
cess occurring locally during AAA. Although we detected peptides con-
taining Trp72 by targeted mass spectrometry, we were unable to detect
their oxidized forms in plasma. However, we could readily detect the
oxidized forms of Trp50 and Trp108, ﬁnding that their relative propor-
tions are increased in plasma of AAA patients when compared to con-
trols. It is also interesting to note that the oxidized forms of Trp50 and
Trp108were independently associated to AAA.Moreover, themodel in-
cluding the oxidized forms of both Trp50 and Trp108 signiﬁcantly im-
proved the accuracy of AAA prediction over that provided by known
risk factors alone. However, for a potential translation to the clinics,
these data must be validated in independent cohorts and novel ap-
proaches based on antibodies speciﬁcally recognizing themodiﬁed pep-
tides should be developed. On the whole, our in vitro and in vivo data
support the association of these novel oxidized forms of APOA1 with
dysfunctional HDL in AAA patients.
4.1. Limitations
One main limitation of our study is the scarce amount of APOA1 in
HDL-like particles that can be obtained from AAA tissue, which makes
it unfeasible to perform functional in vivo studies. This low level is
probably also potentially related to APOA1 oxidation, that promotes
APOA1 dissociation [38]. To circumvent this problem, we have used
HDL isolated from plasma of healthy volunteers incubated ex vivo
with ILT-conditioned media, which contains a representative patho-
physiological composition of AAA molecules. Moreover, it could have
been desirable to compare the effects of ILT-CM with that of healthy-
CM instead of HDL incubated with PBS (HDL-control). However, no ox-
idative or functional differences were observed between HDL incu-
bated with healthy-CM and HDL-control. Moreover, the oxidation of
APOA1 in HDL-like particles recovered from AAA tissues preferentially
affects the same residues (Trp50 and Trp108) when using the ex vivo
model of HDL-ILT CM. Thus, despite the potential limitations of recov-
ering APOA1/HDL from tissue or obtaining healthy-CM to perform
functional experiments, the present study showed that the methods
used herein to examine HDL in the AAA environment could be relevant
for testing the quantity and functional signiﬁcance of modiﬁed HDL
in vivo.
On the whole, our results indicate that APOA1 oxidation in AAA
patients can contribute to dysfunction of HDL particles in AAA charac-
terized by decreased cholesterol efﬂux capacity. Moreover, our prelimi-
nary data in plasma suggest new potential biomarkers (oxidized Trp50
and Trp108 onAPOA1) that could be useful as a surrogate systemicmet-
rics of tissue-HDL functionality.
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